Mounjaro (tirzepatide) affects both GLP-1 and GIP receptors, raising concerns that its digestive-slowing effects may be stronger or more complex than earlier GLP-1 drugs.
Mounjaro often results in gastrointestinal motility disorders because of the characteristics of the medication that slows down gastric emptying (intestinal transit) leading food to remain in the stomach for a longer than normal time period. This process may result in rare cases of gastroparesis (stomach paralysis). However more common side effects are: constipation, nausea, vomiting, severe stomach pain, and diarrhea. Disorders are usually more problematic in the initial few weeks or following when dosage increases.
- Nearly 22 percent of patients with a Mounjaro script suffer through nausea,
- diarrhea (11–17%),
- vomiting, and constipation (4–10%).
Mounjaro inherently slows stomach emptying and alters gut motility to control blood sugar and appetite. While mild slowing is expected, severe motility issues like gastroparesis (stomach paralysis) or chronic constipation require careful management or discontinuation of the medication. Mounjaro mimics gut hormones (GIP and GLP-1) that naturally signal the body to digest food more slowly. While this keeps you feeling full longer, it can sometimes result in prolonged food retention
Motility Disorders Reported With Mounjaro
Patients have reported:
- gastroparesis
- severe constipation
- ileus
- generalized GI dysmotility
Dual-Action Mechanism Concerns
Mounjaro’s dual-action mechanism targets both GIP and GLP-1 receptors. While highly effective for blood sugar control and weight loss, this dual activation introduces specific safety considerations and physiological changes. Gastrointestinal side effects increase nausea and vomiting due to heightened stimulation of metabolic pathways. These side effects cause severe stomach pain, diarrhea, or chronic constipation. Delayed gastric emptying changes how fast your stomach processes food.
Mounjaro’s dual hormone action may:
- intensify
- further slow GI transit
- disrupt gut-brain signaling
In some patients, this appears to lead to prolonged or severe motility impairment.
Common Symptoms
Mounjaro symptoms are primarily digestive, such as nausea, diarrhea, vomiting, and constipation. These are most common when starting the medication or increasing your dose. While most side effects are temporary and mild, severe or persistent symptoms can indicate serious medical issues requiring immediate attention
- persistent nausea and vomiting
- inability to eat normally
- abdominal pain and distension
- dehydration
Legal Context
Mounjaro works in part by intentionally slowing how quickly your stomach empties (gastric motility). While helpful for blood sugar and weight loss, this process can trigger significant gastrointestinal side effects. For a minority of users, this mechanism can result in severe, sometimes long-lasting digestive conditions, including gastroparesis (stomach paralysis)
Mounjaro motility disorder claims focus on:
- severity of digestive injury
- permanence of symptoms
- failure to warn of extreme motility suppression
➡️ Related: Motility Disorders
Mounjaro-related motility disorders can result in long-term digestive disability. These injuries are now actively evaluated within GLP-1 litigation.